Executives and board members at various companies led by Elon Musk are reportedly growing concerned about his ongoing drug use, according to a report in the Wall Street Journal. Sources familiar with Musk and his businesses claim that he continues to consume drugs, particularly ketamine, despite his prescription for the substance as an antidepressant. The report further alleges that Musk has used LSD, cocaine, ecstasy, and psychedelic mushrooms at private parties. However, Musk’s lawyer has stated that he is subjected to regular and random drug testing at SpaceX and has never failed a test.
One incident that drew attention to Musk’s drug use was his public consumption of marijuana during a podcast with Joe Rogan in September 2018. The Pentagon subsequently reviewed the federal security clearance tied to his role as CEO of SpaceX. Musk responded to the accusation on social media, stating that he agreed to three years of random drug testing at NASA’s request after the podcast and that no trace amounts of drugs or alcohol were found.
The report also mentions Linda Johnson Rice, a Tesla director since 2017, who allegedly did not seek reelection due to frustration with Musk’s behavior and drug use.
Elon Musk is known for overseeing six companies: Tesla, SpaceX, X (formerly known as Twitter), The Boring Co., Neuralink, and xAI – an artificial intelligence startup.
While concerns about Musk’s drug use and behavior have been raised, it is essential to present a balanced view and consider different perspectives. The impact of his drug use on his professional responsibilities and the effectiveness of his leadership should be thoroughly assessed. Companies and their stakeholders may need to address these concerns and evaluate the potential consequences for their respective organizations.
As this news highlights ongoing concerns surrounding one of the most influential figures in the tech industry, it is crucial to monitor how these revelations may impact Musk’s business ventures and relationships with stakeholders moving forward.